We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

This study is currently recruiting participants.
Verified April 2017 by National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
First Posted: March 15, 2011
Last Update Posted: April 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza. This study will examine one of these medications, oseltamivir, to examine how it affects the shedding of influenza virus in infected people.

Condition Intervention
Influenza, Human Drug: Oseltamivir Drug: Oseltamivir Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults

Resource links provided by NLM:

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Primary Endpoint is the percentage of subjects shedding virus by PCR in NP swab at day 3. [ Time Frame: Measured at Day 3 ]

Secondary Outcome Measures:
  • Time to alleviation of influenza clinical symptoms [ Time Frame: Measured at Day 28 ]
  • Time to absence of fever [ Time Frame: Measured at Day 28 ]
  • Time to resumption of normal activity [ Time Frame: Measured at Day 28 ]
  • Number of premature study treatment discontinuations [ Time Frame: Measured at Day 28 ]
  • Proportion of participants who develop bronchitis, pneumonia, or other complications of influenza [ Time Frame: Measured at Day 28 ]
  • Proportion of participants who require hospitalization [ Time Frame: Measured at Day 28 ]
  • 28-day mortality [ Time Frame: Measured at Day 28 ]
  • Duration of viral shedding [ Time Frame: Measured at Day 28 ]
  • Change in viral shedding as a function of time [ Time Frame: Measured at Day 28 ]
  • Area under the curve (AUC) of viral shedding [ Time Frame: Measured at Day 28 ]
  • Frequency of emergence of antiviral resistance [ Time Frame: Measured at Day 28 ]

Estimated Enrollment: 800
Study Start Date: April 2011
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oseltamivir
Participants will receive oseltamivir twice a day for 5 days.
Drug: Oseltamivir
One capsule twice daily of 75 mg oseltamivir; total dose: 150 mg/day for 5 days
Placebo Comparator: Oseltamivir Placebo
Participants will receive oseltamivir placebo twice a day for 5 days.
Drug: Oseltamivir Placebo
One capsule twice daily of oseltamivir placebo; total dose: 2 placebo capsules/day for 5 days

Detailed Description:

Seasonal influenza is responsible for excess hospitalizations and, despite effective antivirals, causes significant morbidity and mortality (about 24,000 deaths each year in the United States alone). The influenza virus that emerged in 2009 (A/California/07/2009 H1N1) caused fewer deaths (12,000 flu-related deaths in the U.S.) but in contrast to seasonal flu, nearly 90% of the deaths with the 2009 H1N1 occurred among people younger than 65 years of age. Although there are four currently licensed anti-influenza medications (amantadine and rimantadine, oseltamivir, and zanamivir), previous studies have not demonstrated conclusively to what extent these medications affect influenza viral shedding. This study will evaluate whether oseltamivir modifies the viral shedding during the treatment of uncomplicated influenza in an adult population and also assess methods to detect viral replication in the upper respiratory tract.

Subjects who present with an influenza-like illness without any risk factors for severe disease will be screened for the study. Those with a confirmatory test for influenza (rapid antigen or polymerase chain reaction [PCR]) will be randomized in a 1:1 manner to receive a blinded study treatment consisting of either the oseltamivir or placebo for 5 days. Clinical, virologic, and laboratory assessments on Days 1, 3, 7, and 28 will be used for both safety and efficacy analysis.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent prior to initiation of any study procedures
  • History of an influenza-like illness defined as:

    1) One or more respiratory symptom (cough, sore throat, or nasal symptoms)

  • Onset of illness no more than 48 hours before screening, defined as when the participant experienced at least one respiratory symptom
  • Willing to have samples stored
  • Positive test for influenza (either rapid antigen or polymerase chain reaction [PCR]); randomization may proceed in cases of discrepant results (one positive and one negative)

Exclusion Criteria:

  • Hospitalization at the time of screening
  • Presence of a medical condition(s) that has been associated with increased risk of complications from influenza

    1. Age 65 years of age or older
    2. Asthma
    3. Neurological and neuro-developmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle, such as cerebral palsy, epilepsy [seizure disorders], stroke, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
    4. Chronic lung disease (such as chronic obstructive pulmonary disease [COPD] or cystic fibrosis)
    5. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease)
    6. Blood disorders
    7. Endocrine disorders (such as diabetes mellitus)
    8. Kidney disorders
    9. Liver disorders
    10. Metabolic disorders (such as inherited metabolic disorders or mitochondrial disorders)
    11. Weakened immune system due to disease or medication (such as people with HIV/AIDS or cancer, or use of chronic steroids or other medications causing immune suppression)
    12. Pregnant or 4 weeks postpartum
    13. Body mass index (BMI) greater than or equal to 40
  • Breastfeeding
  • Inability to take oral medication or a history of gastrointestinal malabsorption that would preclude the use of oral medication
  • Received more than one dose of any antiviral influenza medication since onset of influenza symptoms
  • Known end stage kidney dysfunction (e.g., creatinine clearance less than 30 mL/min)
  • Known hypersensitivity to oseltamivir, peramivir, or zanamivir
  • Received live attenuated influenza virus vaccine within 3 weeks prior to study entry
  • Use of any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study entry
  • Participation in other research protocols that require more than 100mL of blood to be drawn in a 4-week period that overlaps with this study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314911

  Hide Study Locations
United States, Arizona
East Valley Family Physicians Recruiting
Chandler, Arizona, United States, 85224
Contact: Kylie Scheldeler, R.N., C.C.R.C.    460-782-5552    kyliescheideler@radiantresearch.com   
Principal Investigator: Donna DeSantis, M.D.         
United States, California
WCCT Global, LLC Terminated
Costa Mesa, California, United States, 92626
Paragon Rx Clinical Recruiting
Garden Grove, California, United States, 92840
Contact: Caitlynn Musil    714-655-5382    caitlynn.musil@prxclinical.com   
Principal Investigator: Hoang Nguyen, M.D.         
Torrance Clinical Research Institute, Inc. Withdrawn
Lomita, California, United States, 90717
University of Southern California 5P21 Rand Schrader Clinic Terminated
Los Angeles, California, United States, 90033
University of California, San Diego Terminated
San Diego, California, United States, 92103
Westlake Medical Research Terminated
Thousand Oaks, California, United States, 91360
Advanced Rx Clinical Research Group Recruiting
Westminster, California, United States, 92683
Contact: Vincent Dinh    714-898-7900    v.dinh@arcrinc.com   
Principal Investigator: Dinh V. Dinh, D.O.         
United States, Colorado
University of Colorado Terminated
Aurora, Colorado, United States, 80045
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610-0186
Contact: Meenakshi Puthucode Balakrishnan, Ph.D.    352-265-5911    meenakshipb@ufl.edu   
Principal Investigator: Marie-Carmelle Elie, M.D.         
Best Quality Research, Inc. Terminated
Hialeah, Florida, United States, 33106
San Marcus Research Clinic Withdrawn
Miami, Florida, United States, 33015
Medical Consulting Center Terminated
Miami, Florida, United States, 33125
Suncoast Research Group, LLC Terminated
Miami, Florida, United States, 33135
University of Miami AIDS Clinical Research Unit Withdrawn
Miami, Florida, United States, 33136
DMI Research, Inc. Active, not recruiting
Pinellas Park, Florida, United States, 33782
United States, Georgia
Columbus Regional Research Institute Recruiting
Columbus, Georgia, United States, 31904
Contact: Alyssa Middlebrook    706-321-0495      
Principal Investigator: Jeffrey Jenkins, M.D.         
United States, Illinois
Sneeze, Wheeze & Itch Associates, LLC Withdrawn
Normal, Illinois, United States, 61761
United States, Iowa
Clinical Research Advantage, Inc. Recruiting
Council Bluffs, Iowa, United States, 51503
Contact: Jan Mitchell    712-352-0423    JanMitchell@radiantresearch.com   
Principal Investigator: Jennifer Kay, M.D.         
University of Iowa Terminated
Iowa City, Iowa, United States, 52242
United States, Kentucky
University of Louisville Hospital Withdrawn
Louisville, Kentucky, United States, 40202
Research Integrity, LLC Terminated
Owensboro, Kentucky, United States, 42303
United States, Louisiana
Horizon Research Group of Opelousas, LLC Recruiting
Eunice, Louisiana, United States, 70535
Contact: Rachael Boudreaux    337-457-8841    rachael@horizonresearchgroup.com   
Principal Investigator: Zebediah Stearns, M.D.         
Michael Seep, MD; Centex Studies Recruiting
Lake Charles, Louisiana, United States, 70601
Contact: Louis Charles    337-244-6374    lcharles@centexstudies.com   
Contact: Amber Victor    337-433-3441    avictor@centexstudies.com   
Principal Investigator: Michael Seep, M.D.         
United States, Maryland
National Institutes of Health, Laboratory of Immunoregulation Terminated
Bethesda, Maryland, United States, 20892
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Guruprasad Jambaulikar    617-525-8466    gjambaulikar@partners.org   
Principal Investigator: Raghu Seethala, M.D., MSc         
United States, Michigan
Henry Ford Hospital Withdrawn
Detroit, Michigan, United States, 48202
Bronson Healthcare Group Withdrawn
Kalamazoo, Michigan, United States, 49007
United States, Nebraska
Skyline Medical Center Recruiting
Elkhorn, Nebraska, United States, 68022
Contact: Shayla Addison, MS, CCRC    402-614-5083    shaylaaddison@radiantresearch.com   
Principal Investigator: William Fitzgibbons         
Prairie Fields Family Medicine Recruiting
Fremont, Nebraska, United States, 68025
Contact: Shayla Addison, MS, CCRC    402-753-6034    shaylaaddison@radiantresearch.com   
Principal Investigator: Thomas Wolf, MD         
Southwest Family Physicians Terminated
Omaha, Nebraska, United States, 68124
United States, New Jersey
New Jersey Medical School Terminated
Newark, New Jersey, United States, 07103
United States, New York
James J. Peters VA Medical Center Withdrawn
Bronx, New York, United States, 10468
NYU School of Medicine Terminated
New York, New York, United States, 10016
Mount Sinai Medical Center Terminated
New York, New York, United States, 10029
University of Rochester Medical Center Terminated
Rochester, New York, United States, 14642
Great Lakes Medical Research Recruiting
Westfield, New York, United States, 14787
Contact: Jennifer Ferreira    716-326-4890    jferreira@glmr.info   
Principal Investigator: Timothy Kitchen, M.D.         
United States, North Carolina
Duke University Medical Center Withdrawn
Durham, North Carolina, United States, 27710
United States, Ohio
Clinical Research Solutions Recruiting
Middleburg Heights, Ohio, United States, 44130
Contact: Kristen Tenhagen    440-340-9010    ktenhagen@crssites.com   
Principal Investigator: Lawrence A. Gervasi, M.D.         
United States, Pennsylvania
University of Pennsylvania, Division of Infectious Disease Terminated
Philadelphia, Pennsylvania, United States, 19104
Frontier Clinical Research, LLC Recruiting
Smithfield, Pennsylvania, United States, 15478
Contact: Kim Chapman    724-569-8100 ext 207    kchapman@frontierclinical.com   
Principal Investigator: Marcy Goisse, M.D.         
United States, South Dakota
Health Concepts Recruiting
Rapid City, South Dakota, United States, 57702
Contact: Marty Beasley    605-721-5094    mbeasley@rchealthconcepts.com   
Principal Investigator: Richard Beasley, M.D.         
United States, Tennessee
Clinical Research Solutions Recruiting
Franklin, Tennessee, United States, 37067
Contact: Debra Adamson, M.S.    615-577-4017    dadamson@crssites.com   
Principal Investigator: Alex Slandzicki, M.D.         
Clinical Research Solutions Recruiting
Jackson, Tennessee, United States, 38305
Contact: Amy Arnold, B.S., C.C.R.C.    731-431-5027    aarnold@crssites.com   
Principal Investigator: Melanie Hoppers, M.D.         
Clinical Research Solutions Recruiting
Smyrna, Tennessee, United States, 37167
Contact: Tammy Davey, CRC    615-984-3362    tdavey@crssites.com   
Principal Investigator: Heather Rowe, M.D.         
United States, Texas
University of Texas Tech Amarillo Terminated
Amarillo, Texas, United States, 79106
University of Texas Health Science Center at Houston Terminated
Houston, Texas, United States, 77030
Centex Studies Recruiting
Houston, Texas, United States, 77058
Contact: Cecil Fontenot, A.A.    281-282-0808    cfontenot@centexstudies.com   
Principal Investigator: Joe Pouzar, M.D.         
Pioneer Research Solutions, Inc. Withdrawn
Houston, Texas, United States, 77098
Texas Tech University Health Sciences Center Terminated
Lubbock, Texas, United States, 79430
Village Health Partners Recruiting
Plano, Texas, United States, 75024
Contact: Madhavi Ampajwala, M.D.    972-354-1520    mampajwalamd@acrctrials.com   
Principal Investigator: Madhavi Ampajwala, M.D.         
Bandera Family Health Care Terminated
San Antonio, Texas, United States, 78249
United States, Virginia
University of Virginia, Elson Student Health Center Withdrawn
Charlottesville, Virginia, United States, 22908
Virginia Commonwealth University Medical Center Terminated
Richmond, Virginia, United States, 23298
Hospital Italiano de Buenos Aires Withdrawn
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 01181
Centro de Educacion Medica e Investigaciones Clinicas (CEMIC) Withdrawn
Buenos Aires, Argentina
Hospital General de Agudos J. M. Ramos Mejía Terminated
Buenos Aires, Argentina
Hospital Público Descentralizado Dr. Guillermo Rawson Terminated
Cordoba, Argentina, 05000
Hospital Municipal "Prof. Dr. Bernardo A. Houssay" Terminated
Pcia. De Buenos Aires, Argentina
The Bamrasnaradura Infectious Diseases Institute Recruiting
Muang, Nonthaburi, Thailand, 1100
Contact: Weerawat Manosuthi, MD    66-2-590-3421    drweerawat@hotmail.com   
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) Recruiting
Bangkok, Thailand, 10330
Contact: Kiat Ruxrungtham, MD, MSc    66-2-652-3040 to 9 ext 107, 147    rkiat@chula.ac.th   
Siriraj Hospital Terminated
Bangkok, Thailand, 10700
Khon Kaen University (Department of Medicine) Recruiting
Khon Kaen, Thailand, 40002
Contact: Ploenchan Chetchotisakd, MD (PI)    66-43-363168    ploencha@kku.ac.th   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Study Chair: John Beigel, MD Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, National Institutes of Health
Study Chair: Michael Ison, MD, MS Division of Infectious Disease, Feinberg School of Medicine, Northwestern University
  More Information

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01314911     History of Changes
Other Study ID Numbers: IRC 004
First Submitted: March 3, 2011
First Posted: March 15, 2011
Last Update Posted: April 5, 2017
Last Verified: April 2017

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Seasonal Influenza
Viral Shedding

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action